Navigation Links
AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
Date:9/21/2009

cokinetic study on weekly oral AEZS-112, a small molecule anti-cancer agent in patients with advanced cancer and lymphoma", was presented by D. W. Northfelt, M.D.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
2. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
3. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
5. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
6. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
7. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
9. AEterna Zentaris Receives US$10 Million from Institutional Investors
10. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
11. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 Dr. Sparano is ... Women’s Health at the Albert Einstein College of Medicine ... the Montefiore Medical Center. He is also Associate ... and leads the Einstein Breast Cancer Working Group, a ... breast cancer research. He also serves as Vice Chair ...
(Date:5/17/2013)... provider of scientific, technical and medical information products and ... in Reproductive BioMedicine Online on ... abnormal chromosomal composition can be identified by the rate ... the risk of genetic abnormality without a biopsy. In ... retrospective study, using their predictive model to assess the ...
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine Group ... 50% enrollment of the total projected enrollment required ... safety and preliminary efficacy of the medical technology ... Knee Osteoarthritis (KOA). To date the trial has ... The Phase I open label clinical research ...
(Date:5/17/2013)... 17, 2013 Men’s skin is biologically different ... Posay ) and has been known to react more aggressively ... may be far from puberty, other acne causing factors like ... breakouts, and threatening skin with unsightly acne scars. Adult acne ... Men’s Health on how to reduce and prevent acne ...
Breaking Biology Technology:Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2
... Calif., Oct. 1 Vet-Stem, Inc. announced that Dr. ... a talk entitled "Stem Cell Therapy: Mechanisms of Action" ... of Veterinary Surgeons (ACVS) in Seattle, WA, October 21, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20060425/VETSTEMLOGO ) Dr. Harman ...
... a pilot-scale study wherein Kibow(R) Biotics were administered orally ... Argentina and Nigeria. The positive outcome from this study ... the peer-reviewed "Advances in Therapy" journal. This report, titled ... Kidney Function in Patients with Chronic Kidney Disease," can ...
... Oct. 1 Bioheart, Inc. - (OTC Bulletin Board: ... discovery, development and commercialization of autologous cell therapies for ... company received a preliminary commitment from Seaside National Bank ... used to refinance the Company,s loan with Bank of ...
Cached Biology Technology:Vet-Stem CEO to Present Invited Talk at Veterinary Surgery Meeting 2Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health 2Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health 3Bioheart, Inc. Announces Loan to be Assumed by Seaside 2Bioheart, Inc. Announces Loan to be Assumed by Seaside 3
(Date:5/16/2013)... living closer to a fast food restaurant had a ... further away from fast food, according to researchers at ... this association was particularly strong among those with a ... in the American Journal of Public Health ... fast food restaurant, and among lower-income African-Americans, the density, ...
(Date:5/16/2013)... The relationship between the heritable risk for ... clear. Schizophrenia is commonly associated with cognitive impairments ... that reduced IQ may be linked to the ... ability may precede the onset of schizophrenia symptoms. ... relatives of people diagnosed with schizophrenia. , In ...
(Date:5/16/2013)... Infections can trigger hematopoiesis at sites outside the bone ... skin.Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich now show that ... medullary" formation of blood cells. , Balanced hematopoiesis is ... fetal development, hematopoiesis takes place mainly in the liver ... the bone marrow, and this tissue normally serves as ...
Breaking Biology News(10 mins):Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Genetic risk for schizophrenia is connected to reduced IQ 2Herpes infections: Natural killer cells activate hematopoiesis 2
... Residential washing machines may not always use hot ... aureus (MRSA) and Acinetobacter, a Gram-negative bacteria, from hospital ... issue of Infection Control and Hospital Epidemiology , ... America. The study, conducted by researchers from ...
... SAN DIEGO (October 2, 2011) Researchers at the ... previously unknown mechanism that generates protective immune memory cells ... which include the mouth, the intestines, the lungs and other ... viruses and other infectious organisms. The findings were published ...
... the Institute for Genomic Biology (IGB) and the School ... NSF,s Integrative Graduate Education and Research Traineeship (IGERT) is ... 1998 and has, thus far, provided interdisciplinary research training ... of Illinois grant, Vertically Integrated Training With Genomics (VInTG), ...
Cached Biology News:Study: Residential washers may not kill hospital-acquired bacteria 2La Jolla Institute discovers novel mechanism for preventing infection via body's mucosal borders 2La Jolla Institute discovers novel mechanism for preventing infection via body's mucosal borders 3La Jolla Institute discovers novel mechanism for preventing infection via body's mucosal borders 4Institute for Genomic Biology, School of Integrative Biology receive major NSF training grant 2
Immunogen: Extract of pigmented melanoma metastases from lymph nodes. Storage: -20 C, Avoid Freeze/Thaw Cycles...
alpha N-catenin (C-19)...
... Immunogen: Synthetic peptide derived from the ... 36 protein This peptide sequence is ... another Zymed polyclonal Connexin 36 antibody Cat. ... Connexin 36. Reactivity: Mouse (positive control: ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
Biology Products: